Literature DB >> 16436759

In vitro activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii.

D W Wareham, D C Bean.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16436759      PMCID： PMC1366933          DOI： 10.1128/AAC.50.2.825-826.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  8 in total

1.  Synergy, antagonism, and what the chequerboard puts between them.

Authors:  F C Odds
Journal:  J Antimicrob Chemother       Date:  2003-06-12       Impact factor: 5.790

2.  In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii.

Authors:  Jimmy Yoon; Carl Urban; Christian Terzian; Noriel Mariano; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 3.  Multiresistant acinetobacter in the UK: how big a threat?

Authors:  J Coelho; N Woodford; J Turton; D M Livermore
Journal:  J Hosp Infect       Date:  2004-11       Impact factor: 3.926

4.  Synergy and antagonism are not synonymous with therapeutic advantage and disadvantage.

Authors:  M C Berenbaum
Journal:  J Antimicrob Chemother       Date:  1988-04       Impact factor: 5.790

5.  Reproducibility of the microdilution checkerboard method for antibiotic synergy.

Authors:  K H Rand; H J Houck; P Brown; D Bennett
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

6.  A method for testing for synergy with any number of agents.

Authors:  M C Berenbaum
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

Review 7.  Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians.

Authors:  Rupali Jain; Larry H Danziger
Journal:  Ann Pharmacother       Date:  2004-07-27       Impact factor: 3.154

8.  Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model.

Authors:  Abelardo Montero; Javier Ariza; Xavier Corbella; Alejandro Doménech; Carmen Cabellos; Josefina Ayats; Fe Tubau; Carmen Borraz; Francesc Gudiol
Journal:  J Antimicrob Chemother       Date:  2004-11-16       Impact factor: 5.790
  8 in total
  5 in total

1.  In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant Enterobacteriaceae.

Authors:  Jonathan W Betts; Lynette M Phee; Michael Hornsey; Neil Woodford; David W Wareham
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

2.  In vitro evaluation of ciclopirox as an adjuvant for polymyxin B against gram-negative bacteria.

Authors:  Kwang-sun Kim; Taeyeon Kim; Jae-Gu Pan
Journal:  J Antibiot (Tokyo)       Date:  2015-01-14       Impact factor: 2.649

3.  Synergistic effect of membrane-active peptides polymyxin B and gramicidin S on multidrug-resistant strains and biofilms of Pseudomonas aeruginosa.

Authors:  Marina Berditsch; Thomas Jäger; Nikola Strempel; Thomas Schwartz; Jörg Overhage; Anne S Ulrich
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

4.  Activity of the colistin-rifampicin combination against colistin-resistant, carbapenemase-producing Gram-negative bacteria.

Authors:  Marcela Nastro; Carlos Hernan Rodríguez; Renata Monge; Jonathan Zintgraff; Liliana Neira; Mirta Rebollo; Carlos Vay; Angela Famiglietti
Journal:  J Chemother       Date:  2013-12-06       Impact factor: 1.714

5.  In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases.

Authors:  David W Wareham; David C Bean
Journal:  Ann Clin Microbiol Antimicrob       Date:  2006-04-21       Impact factor: 3.944
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.